Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

INCREASING LUTETIUM PRODUCTION, WHILE LEVERAGING METABOLIC IMAGING TO ENHANCE THERANOSTICS EFFECTIVENESS

Project description

Advancing antibody-radioisotope treatment

Antibody-radioisotope combinations are a targeted therapeutic approach that delivers radioactive isotopes directly to cancer cells by attaching them to antibodies specific to tumour antigens. This method improves treatment efficacy for resistant cancers while minimising damage to surrounding healthy tissue. The EU-funded ILLUMINATE project seeks to address the isotope shortage and side effects for about 30% of patients. Researchers will enhance imaging for better treatment response insights and personalised care. They will also increase isotope production through sustainable methods to ensure availability. Overall, ILLUMINATE is expected to improve radioisotope theranostics and manufacturing.

Objective

Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to common therapies, such as castrate-resistant prostate cancer. Adding Lutetium-177-PSMA (Lu-177-PSMA) to standard care significantly prolongs survival. However, the increased use of Lu-177-based therapies has resulted in an increased demand for this isotope, leading to shortage risks.In addition, despite the success of Lu-177-treatment, ~30% of patients do not benefit from treatment, but do suffer from side-effects.

ILLUMINATE, will improve the availability and use of theranostics across its value chain by taking a hybrid approach: 1) Imaging capabilities will be improved by implementing novel, broadly applicable, scalable and highly effective Metabolic Magnetic Resonance Imaging (MeMRI), which are expected to give better and faster insight into treatment responses, allowing better patient stratification
and treatment personalisation; 2) The availability of Lu-177 will be fortified by improving its manufacturing process, and by developing sustainable production methods to help meet the general need for radio-isotope based therapies and increase EU autonomy. The ILLUMINATE consortium (industries Philips, NRG, Bracco, TeslaDC, Wavetronica, Lygature, SDN, EuroBioImaging, and the Univerisities of Torino, Lund, Amsterdam UMC, Klinik Essen, coordinated by UMC Utrecht) uses the example of Lu-177-PSMA as a showcase clinical trial in 150 patients for broadly applicable innovative technologies in the field of theranostics and radioisotope manufacturing for oncology.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-JU-IHI-2023-05

See all projects funded under this call

Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 561 000,00
Address
HEIDELBERGLAAN 100
3584 CX Utrecht
Netherlands

See on map

Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 561 000,00

Participants (14)

My booklet 0 0